Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis - PubMed (original) (raw)
Review
Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis
Jorge E Toblli et al. Arzneimittelforschung. 2007.
Abstract
Iron(III)-hydroxide polymaltose complex (IPC) is an iron preparation with non-ionic iron and polymaltose in a stable complex. The usefulness of IPC in the treatment of iron deficiency anemia (IDA) has recently been a topic of much debate. By reviewing the published literature an overview is provided of the existing comparative evidence vs. ferrous sulfate as reference. For this purpose the standard methods and criteria as described by the Cochrane group are employed. The aim was to establish whether there are differences concerning efficacy (primary end-point: hemoglobin after approx. 2 months of treatment) and concerning safety (number of patients with adverse drug reactions [ADRs]). From an initial group of 14 comparative trials identified, 6 comparative studies (1 double blind) conducted in adults could be retained for analysis. Four pediatric studies initially selected had to be rejected because of heterogeneity of data at baseline. In adults (319 IPC, 238 ferrous sulfate) at the end of the study period (8-13 weeks) the mean hemoglobin values were 12.13 +/- 1.19 g/dl with IPC vs. 11.94 +/- 1.84 g/dl with ferrous sulfate (weighted mean difference WMD = 0.01 [95% CI -0.23, 0.21] g/dl). Not all studies reported on ferremia (higher with IPC), transferrin saturation (no difference) or ferritin (lower with IPC). Adverse drug reactions were reported less frequently with IPC (14.9%) than with ferrous sulfate (34.1%; p < 0.001), particularly upper digestive troubles, stained teeth and diarrhea. The meta-analysis of studies conducted in adult patients with iron deficiency anemia, comparing IPC with ferrous sulfate in equivalent doses, showed that the two compounds attained similar hemoglobin levels, thus suggesting similar efficacy. The tolerance of IPC in adults was clearly better than that of ferrous sulfate; the differences were also significant for the individual adverse reactions. This probably reflects a better risk/benefit ratio of IPC in adults. Properly conducted randomized controlled trials, particularly in pediatrics, are needed.
Similar articles
- Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience.
Geisser P. Geisser P. Arzneimittelforschung. 2007;57(6A):439-52. doi: 10.1055/s-0031-1296693. Arzneimittelforschung. 2007. PMID: 17691594 Review. - Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study.
Ortiz R, Toblli JE, Romero JD, Monterrosa B, Frer C, Macagno E, Breymann C. Ortiz R, et al. J Matern Fetal Neonatal Med. 2011 Nov;24(11):1347-52. doi: 10.3109/14767058.2011.599080. Epub 2011 Aug 23. J Matern Fetal Neonatal Med. 2011. PMID: 21859366 Clinical Trial. - Ferrous sulfate versus iron polymaltose complex for treatment of iron deficiency anemia in children.
Bopche AV, Dwivedi R, Mishra R, Patel GS. Bopche AV, et al. Indian Pediatr. 2009 Oct;46(10):883-5. Epub 2009 Apr 1. Indian Pediatr. 2009. PMID: 19430060 Clinical Trial. - [Comparative evaluation of efficacy and tolerance of iron polymaltose complex and ferrous sulphate for treatment of iron deficiency anemia in infants].
Amaral D, Galimberti G, Cuesta S, Pinto J, Ferrario C, Graciela E. Amaral D, et al. Rev Fac Cien Med Univ Nac Cordoba. 2012;69(2):97-101. Rev Fac Cien Med Univ Nac Cordoba. 2012. PMID: 23286539 Clinical Trial. Spanish. - Lactoferrin efficacy versus ferrous sulfate in curing iron deficiency and iron deficiency anemia in pregnant women.
Paesano R, Berlutti F, Pietropaoli M, Pantanella F, Pacifici E, Goolsbee W, Valenti P. Paesano R, et al. Biometals. 2010 Jun;23(3):411-7. doi: 10.1007/s10534-010-9335-z. Epub 2010 Apr 21. Biometals. 2010. PMID: 20407805 Review.
Cited by
- Comparison of the effect of ferrous sulfate and ferrous gluconate on prophylaxis of iron deficiency in toddlers 6-24 months old: A randomized clinical trial.
Falahati V, Ghasemi A, Ghaffari K, Eghbali A, Khodabakhshi S, Almasi-Hashiani A, Sadeghi-Sedeh B, Shanbehzadeh M. Falahati V, et al. J Educ Health Promot. 2022 Nov 26;11:368. doi: 10.4103/jehp.jehp_1764_21. eCollection 2022. J Educ Health Promot. 2022. PMID: 36618468 Free PMC article. - Lactoferrin versus iron hydroxide polymaltose complex for the treatment of iron deficiency anemia in children with cerebral palsy: a randomized controlled trial.
Omar OM, Assem H, Ahmed D, Abd Elmaksoud MS. Omar OM, et al. Eur J Pediatr. 2021 Aug;180(8):2609-2618. doi: 10.1007/s00431-021-04125-9. Epub 2021 May 28. Eur J Pediatr. 2021. PMID: 34101010 Clinical Trial. - Effectiveness of iron polymaltose complex in treatment and prevention of iron deficiency anemia in children: a systematic review and meta-analysis.
Mohd Rosli RR, Norhayati MN, Ismail SB. Mohd Rosli RR, et al. PeerJ. 2021 Jan 13;9:e10527. doi: 10.7717/peerj.10527. eCollection 2021. PeerJ. 2021. PMID: 33520436 Free PMC article. Clinical Trial. - Refining Treatment Strategies for Iron Deficient Athletes.
McCormick R, Sim M, Dawson B, Peeling P. McCormick R, et al. Sports Med. 2020 Dec;50(12):2111-2123. doi: 10.1007/s40279-020-01360-2. Sports Med. 2020. PMID: 33057935 Review. - Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial.
Name JJ, Vasconcelos AR, Valzachi Rocha Maluf MC. Name JJ, et al. Curr Pediatr Rev. 2018;14(4):261-268. doi: 10.2174/1573396314666181002170040. Curr Pediatr Rev. 2018. PMID: 30280670 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources